Dose Insider / Glossary / Semaglutide

SemaglutideWhat it is, how it works and where it is sold

Updated November 20, 2026 路 4 min read 路 OZEMPIC, WEGOVY, RYBELSUS and OZEMPIC tablets labels, 2026

Semaglutide is a lab-made version of the gut hormone GLP-1, changed so that it lasts about a week in the body. It belongs to the class of medicines called GLP-1 receptor agonists.

89%Injection, how much of a dose is absorbed
How much of a dose is absorbedSemaglutide bioavailability, by formInjection89%Ozempic and Wegovy tablets1% to 2%Rybelsus tablets0.4% to 1%How much of a dose isabsorbedSemaglutide bioavailability, by formInjection89%Ozempic and Wegovy tablets1% to 2%Rybelsus tablets0.4% to 1%

That is why tablet doses are many times larger than injected ones.

On this page

Novo Nordisk sells it as Ozempic and Rybelsus for type 2 diabetes and as Wegovy for weight, heart risk and a scarring form of fatty liver disease, in weekly injections and daily tablets. The labels give 2017 as its first U.S. approval.1,2,3

How the molecule is built

The labels describe semaglutide as a GLP-1 analog with 94% sequence homology to human GLP-1. Its peptide backbone is produced by yeast fermentation and then changed in three places. Position 8 is modified so that the enzyme DPP-4, which breaks down the body's own GLP-1, cannot degrade it. Position 26 carries a spacer and an 18-carbon fatty acid that makes the molecule bind to albumin, the main protein in blood, and a minor change was made at position 34.1,3

The albumin binding is what makes weekly dosing possible. More than 99% of semaglutide in the blood is bound to albumin, which slows its removal by the kidneys and protects it from breakdown. The result is an elimination half-life of about 1 week, and the label says semaglutide stays in the circulation for about 5 weeks after the last dose.1

How it works

Semaglutide binds to and activates the GLP-1 receptor. On blood sugar, it raises insulin release and lowers glucagon release, both only when glucose is high, and it causes a minor delay in stomach emptying soon after a meal.1 On weight, the Wegovy label says it decreases calorie intake, likely by acting on appetite, and that the GLP-1 receptor is present in several brain areas involved in appetite regulation. The same label notes that it lowers body weight with greater loss of fat mass than of lean mass.2

The products that contain it

ProductFormDoses mgApproved for
OzempicWeekly injection0.25 to 2Type 2 diabetes, heart and kidney risk
Ozempic tabletsDaily tablet1.5 to 9Type 2 diabetes, heart risk
RybelsusDaily tablet3 to 14Type 2 diabetes, heart risk
WegovyWeekly injection0.25 to 7.2Weight, heart risk, MASH
Wegovy tabletsDaily tablet1.5 to 25Weight, heart risk

Current FDA labels; the heart and kidney uses are each for specific groups of adults named on the label.1,2,3

The milligrams are not comparable across forms. The Rybelsus and Ozempic tablets label says even those two tablets are not substitutable milligram for milligram.3 Any switch between products follows the prescriber's instructions and the label's own switching rules. Our page on Ozempic and Wegovy compares the two injection labels in full.

Injection and tablet in the body

The gap in doses comes from absorption. After an injection under the skin, 89% of the dose reaches the blood, and the level peaks 1 to 3 days later; with weekly doses it reaches a steady state after 4 to 5 weeks.1 A tablet is absorbed mostly in the stomach, with the help of an absorption enhancer called SNAC. Only 0.4% to 1% of a Rybelsus tablet reaches the blood, and 1% to 2% of an Ozempic or Wegovy tablet, with the peak about an hour after the dose.2,3 Because so little is absorbed, the tablets have strict rules: taken on an empty stomach in the morning with up to 4 ounces of water, and nothing else by mouth for at least 30 minutes. Our page on how to take the Wegovy pill shows what the label's absorption studies found.

Safety in brief

Every semaglutide label carries a boxed warning about thyroid C-cell tumors seen in rodents, noting that it is not known whether semaglutide causes them in people. The labels rule it out for people with a personal or family history of medullary thyroid carcinoma or with multiple endocrine neoplasia syndrome type 2. The most common side effects are nausea, vomiting, diarrhea, abdominal pain and constipation.1,2,3 Our page on Ozempic side effects gives the rates.

Compounded semaglutide

Semaglutide made by compounding pharmacies is not an FDA-approved product, and the agency does not review compounded drugs for safety, effectiveness or quality before they are sold. FDA declared the semaglutide shortage over in February 2025.4 As of May 31, 2026 it had received 990 adverse event reports about compounded semaglutide.5 Our page on compounded semaglutide sets out what FDA still allows.

Tirzepatide, the molecule in Mounjaro and Zepbound, acts on the GLP-1 receptor and on a second one, the GIP receptor. Our pages on Ozempic and Wegovy and on compounded semaglutide go further.

Sources

  1. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; sections 1, 2, 3, 11, 12 and boxed warning. accessdata.fda.gov
  2. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; sections 1, 2, 3, 6.1 and 12. accessdata.fda.gov
  3. RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information, revised January 2026. Novo Nordisk; DailyMed, U.S. National Library of Medicine, version published August 19, 2026; sections 1, 2, 3, 11 and 12. dailymed.nlm.nih.gov
  4. U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Entries of December 19, 2024 to April 1, 2026. fda.gov
  5. U.S. Food and Drug Administration. FDA's concerns with unapproved GLP-1 drugs used for weight loss. Content current as of October 1, 2026. fda.gov

Related analyses

Log each semaglutide dose and see your estimated level week by week.

Open Dose Insider